|
Re: Blood
|
4
|
Resverlogix Corp.
|
Jan 20, 2016 01:35PM
|
|
Re: BIO-Europe Presentation is up
|
1
|
Resverlogix Corp.
|
Nov 07, 2017 12:29PM
|
|
Re: BETonMACE top line data
|
2
|
Resverlogix Corp.
|
Jan 18, 2018 08:30PM
|
|
Re: BearDown, Ledenfrog, Tundup and all other experts.....
|
8
|
Resverlogix Corp.
|
Oct 20, 2015 12:10AM
|
|
Re: Award of deferred shares and restricted shares
|
2
|
Resverlogix Corp.
|
Dec 21, 2020 12:44PM
|
|
Re: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
|
10
|
Resverlogix Corp.
|
Mar 17, 2022 07:58PM
|
|
Re: Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
|
7
|
Resverlogix Corp.
|
Jan 12, 2021 08:58PM
|
|
Re: Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
|
7
|
Resverlogix Corp.
|
Mar 03, 2021 07:37PM
|
|
Re: Anyone.....
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 03:01PM
|
|
Re: anyone thinking halt for NR before presentation tomorrow?
|
2
|
Resverlogix Corp.
|
Oct 12, 2016 08:44PM
|
|
Re: Any forced selling going on?
|
3
|
Resverlogix Corp.
|
Jun 24, 2019 08:47PM
|
|
Re: Any catalysts in Q1 to awaken the masses? & BLOOD!
|
5
|
Resverlogix Corp.
|
Jan 20, 2016 01:50PM
|
|
Re: AKA Bill Clinton..."It depends on how you define soon"
|
1
|
Resverlogix Corp.
|
Sep 23, 2016 02:12PM
|
|
Re: AGM... attendees...
|
3
|
Resverlogix Corp.
|
Dec 08, 2016 10:45AM
|
|
Re: Address your Shareholders Donald J. McCaffrey
|
3
|
Resverlogix Corp.
|
May 20, 2020 07:43PM
|
|
Re: Actual salaries paid
|
5
|
Resverlogix Corp.
|
May 22, 2021 07:20PM
|
|
Re: Actions Speak Louder Than Words
|
|
Resverlogix Corp.
|
Nov 21, 2016 07:22PM
|
|
Re: A Shenzhen Hepalink M&A type deal...
|
1
|
Resverlogix Corp.
|
Jan 06, 2018 06:05PM
|
|
Re: A Shenzhen Hepalink M&A type deal...
|
2
|
Resverlogix Corp.
|
Jan 06, 2018 08:21PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
3
|
Resverlogix Corp.
|
May 11, 2017 06:51PM
|
